NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01969877,A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.,https://clinicaltrials.gov/study/NCT01969877,ARTSCANIII,COMPLETED,"The primary endpoint in this study is to investigate if there is a difference in overall survival in patients with locally advanced head and neck cancer, randomized to either radiotherapy and cetuximab or radiotherapy and cisplatin. A second randomization is performed in patients with T3-T4 tumors; allocated radiotherapy either 68.0 Gy or 73.1 Gy.",NO,Locally Advanced Head and Neck Cancer,DRUG: cetuximab|DRUG: cisplatin,"Overall survival, Every 3 month for 2 years, and every 6 month until 5 years for evaluation of overall survival",,,Lund University Hospital,,ALL,"ADULT, OLDER_ADULT",PHASE3,298,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EudraCT number 2012-001879-37|2012-001879-37,2013-11,2018-04,2018-04,2013-10-25,,2020-09-02,"Gävle Hospital, Gävle, Sweden|Sahlgrenska University Hospital, Göteborg, Sweden|County Hospital Ryhov, Jönköping, Sweden|Central Hospital, Karlstad, Sweden|University Hospital Linköping, Linköping, Sweden|Karolinska Universityhospital, Stockholm, Sweden|Norrland University Hospital, Umeå, Sweden|Västmanlands Hospital Västerås, Västerås, Sweden|University Hospital Örebro, Örebro, Sweden",
